Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma

Glioblastoma (GBM) is the most common and aggressive histologic subtype of brain cancer with poor outcomes and limited treatment options. Here we report the selective overexpression of the protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. PRMT5 silence...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yan, Fengting, Alinari, Lapo, Lustberg, Mark E., Martin, Ludmila Katherine, Cordero-Nieves, Hector M., Banasavadi-Siddegowda, Yeshavanth, Virk, Selene, Barnholtz-Sloan, Jill, Bell, Erica Hlavin, Wojton, Jeffrey, Jacob, Naduparambil K., Chakravarti, Arnab, Nowicki, Michal O., Wu, Xin, Lapalombella, Rosa, Datta, Jharna, Yu, Bo, Gordon, Kate, Haseley, Amy, Patton, John T., Smith, Porsha L., Ryu, John, Zhang, Xiaoli, Mo, Xiaokui, Marcucci, Guido, Nuovo, Gerard, Kwon, Chang-Hyuk, Byrd, John C., Chiocca, E. Antonio, Li, Chenglong, Sif, Said, Jacob, Samson, Lawler, Sean, Kaur, Balveen, Baiocchi, Robert A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959215/
https://ncbi.nlm.nih.gov/pubmed/24453002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-0884
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller